ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,479.63
0.00%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Medicinova Inc (MNOV) Share Price

MNOV Medicinova Inc

1.36
0.03 (2.26%)
31 May 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Medicinova Inc NASDAQ:MNOV NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.03 2.26 1.36 1.30 1.80 1.42 1.36 1.36 35,815 22:08:49   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations 1M -8.57M -0.1748 -8.01 68.66M
 Type  Size  Price  Time  Units 
 9 86 1.36 20:01:16 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore MNOV News
28/05/202411:00GLOBEMediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
20/05/202411:00GLOBEMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
14/05/202411:00GLOBEMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
09/05/202421:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/05/202411:00GLOBEMediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
03/04/202400:00GLOBEMediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
26/03/202423:00GLOBEMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
Period
Draw mode
Data Downloads for MNOV

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Medicinova Inc Articles